改良三甲散治疗老年性痴呆病的免疫炎症机制研究

发布时间：2018-01-01 04:17

  本文关键词：改良三甲散治疗老年性痴呆病的免疫炎症机制研究　出处：《南京中医药大学》2016年硕士论文　论文类型：学位论文

  更多相关文章： 改良三甲散 老年性痴呆病 BV2细胞 PC12细胞

【摘要】：老年性痴呆病又称为阿尔茨海默病(Alzheimer's dementia, AD),是以认知功能障碍、精神行为异常和社会功能减退为主要特点的临床常见的神经退行性疾病,其病因迄今仍不清楚,发病机制尚不完全明确,对于本病目前尚无特效的治疗方法。中医学对本病的认识历史悠久,认为本病属本虚标实之证,本虚多为肝肾亏虚、髓海不充、心脾不足,标实多为气滞血瘀,痰阻脉络,导致使清窍失灵,神机失用,发为痴呆。本文从理论和实验两方面论述了改良三甲散治疗老年性痴呆病的理论基础及作用机制。理论研究部分回顾了中医学和西医学对老年性痴呆病的认识以及改良三甲散治疗老年性痴呆病的前期研究成果。实验部分以BV2细胞及PC12细胞为研究对象,将BV2细胞分为空白对照组、模型组、改良三甲散高、中、低剂量组、石杉碱甲组,待细胞贴壁后改良三甲散组及石杉碱甲组分别加入不同浓度的含药脑脊液,37℃C孵育2h后除空白对照组外均加入LPS(终浓度为1 μg/ml),继续孵育24h后收集培养上清,提取蛋白样品。应用硝酸还原酶法检测各组细胞培养液中NO的含量；应用ELISA法检测各组细胞培养液中iNOS、IL-1β、TNF-α的含量；应用Western blot法检测各组细胞JNK、p-JNK的表达。并以各组BV2细胞培养液作为条件培养液,作用于PC12细胞,24小时后提取蛋白样品,应用Western blot法检测PC12细胞中APP及BACE的表达情况。实验结果显示,与模型组相比,改良三甲散含药脑脊液高、中剂量组NO、iNOS、IL-1β、TNF-α的含量均显著减少(P0.05), p-JNK表达下调；改良三甲散高、中、低剂量组APP表达下调,改良三甲散中、低剂量组BACE表达下调。这提示改良三甲散含药脑脊液可以通过抑制JNK的磷酸化,减少炎性介质和细胞因子的释放,从而减轻激活的BV2细胞对PC12细胞的毒性作用。这可能是改良三甲散治疗老年性痴呆病的作用机制之一。
[Abstract]:Alzheimer's disease, also known as Alzheimer's disease, Alzheimer's dementia, is based on cognitive dysfunction. The etiology and pathogenesis of neurodegenerative diseases, which are mainly characterized by mental and behavioral disorders and social dysfunction, are still unclear. For this disease there is no special treatment. Traditional Chinese medicine has a long history of understanding of this disease, think that this disease is a deficiency of the syndrome, the deficiency of the liver and kidney deficiency, deficiency of the marrow sea, heart and spleen insufficiency, the standard of qi stagnation and blood stasis. Phlegm obstructs the choroid, causes clear orifices to be out of order, the spirit machine loses use. In this paper, the theoretical basis and mechanism of modified Sanjia Powder in the treatment of Alzheimer's disease are discussed from the aspects of theory and experiment. The theoretical research part reviews the understanding of Alzheimer's disease in traditional Chinese medicine and western medicine. And the early research results of modified Sanjia Powder in the treatment of Alzheimer's disease. The experimental part of BV2 cells and PC12 cells as the research object. BV2 cells were divided into blank control group, model group, modified Sanjia powder high, medium, low dose group, Huperzine A group. The modified Sanjia Powder group and Huperzine A group were incubated with different concentrations of CSF at 37 鈩，

本文编号：1362862